Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

[A systematic review on population-based indicators of the quality of care in formal and informal provider networks and their application in health economic evaluations].

Seibert K, Stiefler S, Domhoff D, Wolf-Ostermann K, Peschke D.

Z Evid Fortbild Qual Gesundhwes. 2019 Aug;144-145:7-23. doi: 10.1016/j.zefq.2019.06.004. Epub 2019 Jul 19. Review. German.

PMID:
31327735
2.

Financial Strain and Physical and Emotional Quality of Life in Breast Cancer.

Perry LM, Hoerger M, Seibert K, Gerhart JI, O'Mahony S, Duberstein PR.

J Pain Symptom Manage. 2019 Sep;58(3):454-459. doi: 10.1016/j.jpainsymman.2019.05.011. Epub 2019 Jun 1.

PMID:
31163258
3.

Long-Term Strategy for Assessing Carbonaceous Particulate Matter Concentrations from Multiple Fourier Transform Infrared (FT-IR) Instruments: Influence of Spectral Dissimilarities on Multivariate Calibration Performance.

Debus B, Takahama S, Weakley AT, Seibert K, Dillner AM.

Appl Spectrosc. 2019 Mar;73(3):271-283. doi: 10.1177/0003702818804574. Epub 2018 Nov 13.

PMID:
30223670
4.

Clinical next-generation sequencing in patients with non-small cell lung cancer.

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.

Cancer. 2015 Feb 15;121(4):631-9. doi: 10.1002/cncr.29089. Epub 2014 Oct 24.

5.

Clinical genomicist workstation.

Sharma MK, Phillips J, Agarwal S, Wiggins WS, Shrivastava S, Koul SB, Bhattacharjee M, Houchins CD, Kalakota RR, George B, Meyer RR, Spencer DH, Lockwood CM, Nguyen TT, Duncavage EJ, Al-Kateb H, Cottrell CE, Godala S, Lokineni R, Sawant SM, Chatti V, Surampudi S, Sunkishala RR, Darbha R, Macharla S, Milbrandt JD, Virgin HW, Mitra RD, Head RD, Kulkarni S, Bredemeyer A, Pfeifer JD, Seibert K, Nagarajan R.

AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:156-7. eCollection 2013.

PMID:
24303327
6.

Validation of a next-generation sequencing assay for clinical molecular oncology.

Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, Lockwood CM, Hagemann IS, O'Guin SM, Burcea LC, Sawyer CS, Oschwald DM, Stratman JL, Sher DA, Johnson MR, Brown JT, Cliften PF, George B, McIntosh LD, Shrivastava S, Nguyen TT, Payton JE, Watson MA, Crosby SD, Head RD, Mitra RD, Nagarajan R, Kulkarni S, Seibert K, Virgin HW 4th, Milbrandt J, Pfeifer JD.

J Mol Diagn. 2014 Jan;16(1):89-105. doi: 10.1016/j.jmoldx.2013.10.002. Epub 2013 Nov 6.

7.

The Tanapoxvirus 142R Protein is a Serine-Threonine Kinase that Phosphorylates the Tumor Suppressor p53.

Seibert KN, Essani K, Bejcek BE.

Open Virol J. 2013;7:1-4. doi: 10.2174/1874357901307010001. Epub 2013 Jan 21.

8.

Multidrug donor preconditioning protects steatotic liver grafts against ischemia-reperfusion injury.

von Heesen M, Seibert K, Hülser M, Scheuer C, Wagner M, Menger MD, Schilling MK, Moussavian MR.

Am J Surg. 2012 Feb;203(2):168-76. doi: 10.1016/j.amjsurg.2011.01.026. Epub 2011 Jul 22.

PMID:
21782153
9.

Split-liver procedure and inflammatory response: improvement by pharmacological preconditioning.

von Heesen M, Hülser M, Seibert K, Scheuer C, Dold S, Kollmar O, Wagner M, Menger MD, Schilling MK, Moussavian MR.

J Surg Res. 2011 Jun 1;168(1):e125-35. doi: 10.1016/j.jss.2011.01.036. Epub 2011 Feb 21.

PMID:
21435665
10.

The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.

Wang JL, Carter J, Kiefer JR, Kurumbail RG, Pawlitz JL, Brown D, Hartmann SJ, Graneto MJ, Seibert K, Talley JJ.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):7155-8. doi: 10.1016/j.bmcl.2010.07.053. Epub 2010 Jul 23.

PMID:
21055613
11.

Synthesis of carbamates from diethoxycarbonyl hydrazine derivatives by E1cB eliminative cleavage of the N-N'-bond rather than reduction.

Magnus P, Garizi N, Seibert KA, Ornholt A.

Org Lett. 2009 Dec 17;11(24):5646-8. doi: 10.1021/ol902313v.

PMID:
19908859
12.

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.

Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.

Eur J Pharmacol. 2008 Jun 24;588(1):93-8. doi: 10.1016/j.ejphar.2008.03.057. Epub 2008 Apr 6.

PMID:
18457826
13.

Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice.

Stack CM, Lim MA, Cuasay K, Stone MM, Seibert KM, Spivak-Pohis I, Crawley JN, Waschek JA, Hill JM.

Exp Neurol. 2008 May;211(1):67-84. doi: 10.1016/j.expneurol.2008.01.003. Epub 2008 Jan 19.

14.

Mechanistic implications in the Morita-Baylis-Hillman alkylation: isolation and characterization of an intermediate.

Krafft ME, Haxell TF, Seibert KA, Abboud KA.

J Am Chem Soc. 2006 Apr 5;128(13):4174-5.

PMID:
16568961
15.

Unprecedented reactivity in the Morita-Baylis-Hillman reaction; intramolecular alpha-alkylation of enones using saturated alkyl halides.

Krafft ME, Seibert KA, Haxell TF, Hirosawa C.

Chem Commun (Camb). 2005 Dec 14;(46):5772-4. Epub 2005 Nov 4.

PMID:
16307141
16.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
17.

Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.

Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B, Cullinane D, Einhorn TA.

J Orthop Res. 2003 Jul;21(4):670-5.

18.

Mechanism of inhibition of novel COX-2 inhibitors.

Gierse J, Kurumbail R, Walker M, Hood B, Monahan J, Pawlitz J, Stegeman R, Stevens A, Kiefer J, Koboldt C, Moreland K, Rowlinson S, Marnett L, Pierce J, Carter J, Talley J, Isakson P, Seibert K.

Adv Exp Med Biol. 2002;507:365-9. No abstract available.

PMID:
12664611
19.

Cyclooxygenase-2 in human pathological disease.

Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL.

Adv Exp Med Biol. 2002;507:177-84. Review.

PMID:
12664583
20.

Characterization of celecoxib and valdecoxib binding to cyclooxygenase.

Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB.

Mol Pharmacol. 2003 Apr;63(4):870-7.

PMID:
12644588
21.

Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2.

Gierse JK, Staten NR, Casperson GF, Koboldt CM, Trigg JS, Reitz BA, Pierce JL, Seibert K.

Vet Ther. 2002 Fall;3(3):270-80.

PMID:
12447834
22.

Pharmacology of celecoxib in rat brain after kainate administration.

Ciceri P, Zhang Y, Shaffer AF, Leahy KM, Woerner MB, Smith WG, Seibert K, Isakson PC.

J Pharmacol Exp Ther. 2002 Sep;302(3):846-52.

PMID:
12183639
23.

Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants.

Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS.

Arthritis Rheum. 2002 Jul;46(7):1789-803.

24.

Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.

Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL.

Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. Review.

PMID:
12051953
25.

Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.

Anticancer Res. 2001 Sep-Oct;21(5):3425-32.

PMID:
11848504
26.

A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Walker MC, Kurumbail RG, Kiefer JR, Moreland KT, Koboldt CM, Isakson PC, Seibert K, Gierse JK.

Biochem J. 2001 Aug 1;357(Pt 3):709-18.

27.

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K.

Cancer Res. 2000 Oct 15;60(20):5599-602.

28.

Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.

Alshafie GA, Abou-Issa HM, Seibert K, Harris RE.

Oncol Rep. 2000 Nov-Dec;7(6):1377-81.

PMID:
11032948
29.
30.

Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.

Khanna IK, Yu Y, Huff RM, Weier RM, Xu X, Koszyk FJ, Collins PW, Cogburn JN, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K, Veenhuizen AW, Yuan J, Yang DC, Zhang YY.

J Med Chem. 2000 Aug 10;43(16):3168-85.

PMID:
10956225
31.

N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.

Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K.

J Med Chem. 2000 May 4;43(9):1661-3. No abstract available.

PMID:
10794682
32.

Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.

Harris RE, Alshafie GA, Abou-Issa H, Seibert K.

Cancer Res. 2000 Apr 15;60(8):2101-3.

33.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K.

Cancer Res. 2000 Mar 1;60(5):1306-11.

34.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.

J Med Chem. 2000 Mar 9;43(5):775-7. No abstract available.

PMID:
10715145
35.

COX-2 inhibitors. A new class of antiangiogenic agents.

Masferrer JL, Koki A, Seibert K.

Ann N Y Acad Sci. 1999;889:84-6. Review.

PMID:
10668485
36.

Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV.

Cancer Res. 2000 Jan 15;60(2):293-7.

37.

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ.

Mol Carcinog. 1999 Aug;25(4):231-40.

PMID:
10449029
38.

COX-2 inhibitors--is there cause for concern?

Seibert K, Lefkowith J, Tripp C, Isakson P, Needleman P.

Nat Med. 1999 Jun;5(6):621-2. No abstract available.

PMID:
10371498
39.

Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.

Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto MJ, Seibert K, Koboldt CM, Masferrer J, Zweifel B.

Bioorg Med Chem Lett. 1999 Apr 19;9(8):1171-4.

PMID:
10328307
40.

Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors.

Carter JS, Rogier DJ, Graneto MJ, Seibert K, Koboldt CM, Zhang Y, Talley JJ.

Bioorg Med Chem Lett. 1999 Apr 19;9(8):1167-70.

PMID:
10328306
41.

4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2).

Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Norman BH, Rogier DJ Jr, Zwwifel BS, Seibert K.

Med Res Rev. 1999 May;19(3):199-208. Review.

PMID:
10232649
42.

Kinetic basis for selective inhibition of cyclo-oxygenases.

Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC.

Biochem J. 1999 May 1;339 ( Pt 3):607-14.

43.

Pharmacological analysis of cyclooxygenase-1 in inflammation.

Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8.

44.

Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2.

Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Fürstenberger G.

Mol Carcinog. 1998 Sep;23(1):36-44.

PMID:
9766436
45.

Effect of hydrodynamic and magnetic stabilization on fluidized-Bed adsorption

Seibert KD, Burns MA.

Biotechnol Prog. 1998 Sep;14(5):749-55.

PMID:
9758665
46.

Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ.

Science. 1998 May 22;280(5367):1268-70.

47.

Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.

Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC.

J Pharmacol Exp Ther. 1997 Dec;283(3):1069-75.

PMID:
9399978
48.

Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Kawamori T, Rao CV, Seibert K, Reddy BS.

Cancer Res. 1998 Feb 1;58(3):409-12.

49.

Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope.

Militianu A, Salacata A, Seibert K, Kehoe R, Baga JJ, Meissner MD, Pires LA, Schuger CD, Steinman RT, Mosteller RD, Palti AJ, David JB, Lessmeier TJ, Lehmann MH.

J Cardiovasc Electrophysiol. 1997 Oct;8(10):1087-97.

PMID:
9363811
50.

1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.

Khanna IK, Weier RM, Yu Y, Xu XD, Koszyk FJ, Collins PW, Koboldt CM, Veenhuizen AW, Perkins WE, Casler JJ, Masferrer JL, Zhang YY, Gregory SA, Seibert K, Isakson PC.

J Med Chem. 1997 May 23;40(11):1634-47.

PMID:
9171873

Supplemental Content

Loading ...
Support Center